Artemisinin derivative artesunate induces radiosensitivity in cervical cancer cells in vitro and in vivo

Radiation Oncology

Volumn 9, Issue 1, 2014, Pages

  Luo, Judong ^a,b   Zhu, Wei ^a   Tang, Yiting ^a   Cao, Han ^a   Zhou, Yuanyuan ^a   Ji, Rong ^a   Zhou, Xifa ^b   Lu, Zhongkai ^b   Yang, Hongying ^a   Zhang, Shuyu ^a   Cao, Jianping ^a  

^a MEDICAL COLLEGE OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

Author keywords

Apoptosis; Artesunate (ART); Cell cycle; Cervical cancer; Radiosensitivity

Indexed keywords

ARTESUNATE; CYCLIN B1; PHOSPHATE BUFFERED SALINE; PROTEIN P53; RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER SIZE; CANCER TISSUE; CAPILLARY DENSITY; CELL CYCLE PROGRESSION; CLONOGENIC ASSAY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; ONCOGENE; RADIOSENSITIVITY; RADIOSENSITIZATION; RNA DEGRADATION; RNA TRANSPORT; SIGNAL TRANSDUCTION; SPLICEOSOME; TUMOR XENOGRAFT; UTERINE CERVIX CANCER; X IRRADIATION;

ANIMALS; ARTEMISININS; CARCINOMA; FEMALE; HELA CELLS; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; TUMOR CELLS, CULTURED; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897951955     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-9-84     Document Type: Article

References (38)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011, 61:212-236. 10.3322/caac.20121, 21685461.
2. Kim TJ, Lee JW, Song SY, Choi JJ, Choi CH, Kim BG, Lee JH, Bae DS. Increased expression of pAKT is associated with radiation resistance in cervical cancer. Br J Cancer 2006, 94:1678-1682. 2361323, 16721365.
3. Wang J, Huang L, Li J, Fan Q, Long Y, Li Y, Zhou B. Artemisinin directly targets malarial mitochondria through its specific mitochondrial activation. PLoS One 2010, 5:e9582. 10.1371/journal.pone.0009582, 2833198, 20221395.
4. Ase I, Lai H, Singh NP, Sasaki T. Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm 2008, 354:28-33. 10.1016/j.ijpharm.2007.09.003, 17942255.
5. Efferth T, Romero MR, Wolf DG, Stamminger T, Marin JJ, Marschall M. The antiviral activities of artemisinin and artesunate. Clin Infect Dis 2008, 47:804-811.
6. Zhou C, Pan W, Wang XP, Chen TS. Artesunate induces apoptosis via a Bak-mediated caspase-independent intrinsic pathway in human lung adenocarcinoma cells. J Cell Physiol 2012, 227:3778-3786. 10.1002/jcp.24086, 22378505.
7. Berdelle N, Nikolova T, Quiros S, Efferth T, Kaina B. Artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol Cancer Ther 2011, 10:2224-2233. 10.1158/1535-7163.MCT-11-0534, 21998290.
8. Jiang Z, Chai J, Chuang HH, Li S, Wang T, Cheng Y, Chen W, Zhou D. Artesunate induces G0/G1 cell cycle arrest and iron-mediated mitochondrial apoptosis in A431 human epidermoid carcinoma cells. Anticancer Drugs 2012, 23:606-613. 10.1097/CAD.0b013e328350e8ac, 22421370.
9. Gong XM, Zhang Q, Torossian A, Cao JP, Fu S. Selective radiosensitization of human cervical cancer cells and normal cells by artemisinin through the abrogation of radiation-induced G2 block. Int J Gynecol Cancer 2012, 22:718-724. 10.1097/IGC.0b013e31824a67c9, 22552829.
10. Luo J, Chen X, Chen G, Zhou X, Lu X, Ling Y, Zhang S, Zhu W, Cao J. Dihydroartemisinin induces radiosensitivity in cervical cancer cells by modulating cell cycle progression. Saudi Med J 2009, 34:254-260.
11. Reichert S, Reinboldt V, Hehlgans S, Efferth T, Rodel C, Rodel F. A radiosensitizing effect of artesunate in glioblastoma cells is associated with a diminished expression of the inhibitor of apoptosis protein survivin. Radiother Oncol 2012, 103:394-401. 10.1016/j.radonc.2012.03.018, 22560712.
12. Zhao Y, Jiang W, Li B, Yao Q, Dong J, Cen Y, Pan X, Li J, Zheng J, Pang X. Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2/M phase. Int Immunopharmacol 2011, 11:2039-2046. 10.1016/j.intimp.2011.08.017, 21907831.
13. Liu P, Zhou J, Zhu H, Xie L, Wang F, Liu B, Shen W, Ye W, Xiang B, Zhu X. VEGF-C promotes the development of esophageal cancer via regulating CNTN-1 expression. Cytokine 2011, 55:8-17. 10.1016/j.cyto.2011.03.008, 21482472.
14. Fernet M, Megnin-Chanet F, Hall J, Favaudon V. Control of the G2/M checkpoints after exposure to low doses of ionising radiation: implications for hyper-radiosensitivity. DNA Repair (Amst) 2010, 9:48-57. 10.1016/j.dnarep.2009.10.006, 19926348.
15. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006, 21:3-9.
16. Mir SE, de Witt Hamer PC, Krawczyk PM, Balaj L, Claes A, Niers JM. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma. Cancer Cell 2010, 18:244-257. 10.1016/j.ccr.2010.08.011, 3115571, 20832752.
17. Perry JA, Kornbluth S. Cdc25 and Wee1: analogous opposites?. Cell Div 2007, 2:12. 10.1186/1747-1028-2-12, 1868713, 17480229.
18. Dixon BP, Henry J, Siroky BJ, Chu A, Groen PA, Bissler JJ. Cell cycle control and DNA damage response of conditionally immortalized urothelial cells. PLoS One 2011, 6:e16595. 10.1371/journal.pone.0016595, 3030598, 21305048.
19. Pandey AV, Tekwani BL, Singh RL, Chauhan VS. Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite. J Biol Chem 1999, 274:19383-19388. 10.1074/jbc.274.27.19383, 10383451.
20. Messori L, Gabbiani C, Casini A, Siragusa M, Vincieri FF, Bilia AR. The reaction of artemisinins with hemoglobin: a unified picture. Bioorg Med Chem 2006, 14:2972-2977. 10.1016/j.bmc.2005.12.038, 16412643.
21. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol 2001, 18:767-773.
22. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol 2003, 64:382-394. 10.1124/mol.64.2.382, 12869643.
23. Hamacher-Brady A, Stein HA, Turschner S, Toegel I, Mora R, Jennewein N, Efferth T, Eils R, Brady NR. Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem 2011, 286:6587-6601. 10.1074/jbc.M110.210047, 3057810, 21149439.
24. Concin N, Stimpfl M, Zeillinger C, Wolff U, Hefler L, Sedlak J, Leodolter S, Zeillinger R. Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines. Int J Oncol 2003, 22:51-57.
25. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol 2008, 9:297-308. 10.1038/nrm2351, 18285803.
26. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004, 3:513-519.
27. Leijen S, Beijnen JH, Schellens JH. Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents. Curr Clin Pharmacol 2010, 5:186-191. 10.2174/157488410791498824, 20406171.
28. Liebmann J, Cook JA, Fisher J, Teague D, Mitchell JB. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994, 86:441-446. 10.1093/jnci/86.6.441, 7907149.
29. PosthumaDeBoer J, Wurdinger T, Graat HC, van Beusechem VW, Helder MN, van Royen BJ, Kaspers GJ. WEE1 inhibition sensitizes osteosarcoma to radiotherapy. BMC Cancer 2011, 11:156. 10.1186/1471-2407-11-156, 3103478, 21529352.
30. Owens L, Simanski S, Squire C, Smith A, Cartzendafner J, Cavett V. Activation domain-dependent degradation of somatic Wee1 kinase. J Biol Chem 2010, 285:6761-6769. 10.1074/jbc.M109.093237, 2825470, 20038582.
31. Polidarova L, Sotak M, Sladek M, Pacha J, Sumova A. Temporal gradient in the clock gene and cell-cycle checkpoint kinase Wee1 expression along the gut. Chronobiol Int 2009, 26:607-620. 10.1080/07420520902924889, 19444744.
32. Gravett AM, Liu WM, Krishna S, Chan WC, Haynes RK, Wilson NL, Dalgleish AG. In vitro study of the anti-cancer effects of artemisone alone or in combination with other chemotherapeutic agents. Cancer Chemother Pharmacol 2011, 67:569-577. 10.1007/s00280-010-1355-4, 20490800.
33. Raleigh JM, O'Connell MJ. The G(2) DNA damage checkpoint targets both Wee1 and Cdc25. J Cell Sci 2000, 113(Pt 10):1727-1736.
34. Efeyan A, Serrano M. p53: guardian of the genome and policeman of the oncogenes. Cell Cycle 2007, 6:1006-1010. 10.4161/cc.6.9.4211, 17457049.
35. Kastan MB, Berkovich E. p53: a two-faced cancer gene. Nat Cell Biol 2007, 9:489-491. 10.1038/ncb0507-489, 17473858.
36. Eriksson D, Stigbrand T. Radiation-induced cell death mechanisms. Tumour Biol 2010, 31:363-372. 10.1007/s13277-010-0042-8, 20490962.
37. Lu C, El-Deiry WS. Targeting p53 for enhanced radio- and chemo-sensitivity. Apoptosis 2009, 14:597-606. 10.1007/s10495-009-0330-1, 19259822.
38. Shi J, Hershey JW, Nelson MA. Phosphorylation of the eukaryotic initiation factor 3f by cyclin-dependent kinase 11 during apoptosis. FEBS Lett 2009, 583:971-977. 10.1016/j.febslet.2009.02.028, 2666973, 19245811.